Golden Age Resources (OTCPK:GDAR) - Stock Price, News & Analysis

GDAR Stock Overview

Golden Age Resources Inc., an acquisition and development company, focus on the development of prescription and over the counter medicines in the United States. More details

GDAR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($3K)

Has not reported any financial data

Shares are highly illiquid

Golden Age Resources, Inc. Competitors

Lucy Scientific Discovery

OTCPK:LSDI.F

US$8.8k

Item 9 Labs

OTCPK:INLB

US$701.0

BZAM

OTCPK:BZAM.F

US$270.0

Hero Technologies

OTCPK:HENC

US$563.0

Price History & Performance

Summary of all time highs, changes and price drops for Golden Age Resources
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-90.00%
5 Year Change	-99.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	GDAR	US Pharmaceuticals	US Market
7D	0%	2.6%	0.5%
1Y	n/a	13.1%	30.7%

Return vs Industry: Insufficient data to determine how GDAR performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GDAR performed against the US Market.

Price Volatility

Is GDAR's price volatile compared to industry and market?
GDAR volatility
GDAR Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GDAR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GDAR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	n/a	Daniel Kogan	www.gdarinc.com

Golden Age Resources Inc., an acquisition and development company, focus on the development of prescription and over the counter medicines in the United States. The company offers its products in the areas of cardiovascular, anti-microbial, immunity, arthritis, pain relief, and other therapeutic areas. Its product portfolio include Nitrosorbid, a vasodilator for the treatment of angina pectoris; Ampicillin Trihydrate, an antibiotic-penicillin; Analgin, a pain relief; Corvalol to treat neuroses with heightened irritability/insomnia/hypertension/non-acute spasm of coronary vessels/tachycardia/gastrointestinal cramping; Tubosan, an immune stimulator; and Lovastatin for the treatment of dyslipidemia, as well as for the prevention of cardiovascular diseases.

Golden Age Resources, Inc. Fundamentals Summary

How do Golden Age Resources's earnings and revenue compare to its market cap?
GDAR fundamental statistics
Market cap	US$3.38k
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is GDAR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GDAR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did GDAR perform over the long term?

See historical performance and comparison